TrialBlood cancer journal2020

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.

Alejandro Medina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.